Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.
Abstract: Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
March 24, 2015
Assignee:
Wyeth LLC
Inventors:
Carl Ralph Flannery, Christopher John Corcoran, Bethany Annis Freeman, Lisa A. Collins-Racie
Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
Type:
Grant
Filed:
June 14, 2006
Date of Patent:
March 24, 2015
Assignee:
Bayer Healthcare LLC
Inventors:
Jesper Mortensen Haaning, Kim Vilbour Andersen, Claus Bornaes
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
March 24, 2015
Assignee:
Pfizer Inc.
Inventors:
Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark E. Ruppen
Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a protein digestibility corrected amino acid score (PDCAAS) that exceeds a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.
Type:
Application
Filed:
March 15, 2013
Publication date:
March 19, 2015
Inventors:
Nathaniel W. Silver, Geoffrey von Maltzahn, Michael J. Hamill, David Arthur Berry
Abstract: The invention concerns soluble variants of Treponema pallidum antigen 47 (TpN47 antigen) comprising at least domain B, or at least domains A and B, optionally domain D of the complete TpN47 protein molecule with the proviso that all antigens lack domain C (amino acid residues 224 to 351) of TpN47. The Tpn47 antigens can be fused to a chaperone. Moreover, the invention covers DNA encoding the antigens, a method of producing these antigens as well as the use of these antigens in an immunodiagnostic assay for the detection of antibodies against Treponema pallidum in an isolated sample.
Type:
Application
Filed:
July 18, 2014
Publication date:
March 19, 2015
Inventors:
Elke Faatz, Peter Schaarschmidt, Urban Schmitt, Christian Scholz
Abstract: The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against Plasmodium falciparum. The inventive antigens were identified by their association with sterile immunity against malaria.
Type:
Application
Filed:
September 16, 2013
Publication date:
March 19, 2015
Inventors:
Denise Doolan, Angela Trieu, Phillip L. Felgner
Abstract: The present invention relates to novel polypeptides comprising an ice-binding capability resulting in an ice crystal formation and/or growth reducing or inhibiting activity. The present invention also relates to an edible product and to a solid support comprising the novel polypeptide. Furthermore, the present invention also relates to a method for producing the novel polypeptide and to different uses of the novel polypeptide.
Type:
Application
Filed:
September 9, 2014
Publication date:
March 19, 2015
Inventors:
Hans Ramløv, Casper Wilkens, Anders Løbner-Olesen
Abstract: The disclosure provides a general method for the production of protein variants with a reduced aggregation propensity without affecting the thermodynamic stability of the variant with respect to the wild-type protein.
Type:
Application
Filed:
April 18, 2013
Publication date:
March 19, 2015
Inventors:
Frederic Rousseau, Joost Schymkowitz, Ashok Ganesan, Aleksandra Siekierska, Frederik De Smet, Joost Van Durme
Abstract: This invention provides biosensors, cell models, and methods of their use for monitoring ionic or voltage responses to contact with bioactive agents. Biosensors can include targeting domains, sensing domains and reporting domains. Biosensors can be introduced into cells reprogrammed to represent experimental or pathologic cells of interest. Model cells expressing the biosensors can be contacted with putative bioactive agents to determine possible activities.
Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.
Type:
Application
Filed:
March 26, 2013
Publication date:
March 19, 2015
Applicant:
GE HEALTHCARE BIO-SCIENCES AB
Inventors:
Mats Ander, Goran Bauren, Tomas Bjorkman, Per-Mikael Aberg, Gustav Rodrigo
Abstract: Nitration shielding peptides that reduce or prevent nitration of a protein of interest are disclosed. The peptide can serve as molecular sink for nitrating agents, block access of the nitrating agents to the target tyrosine on the protein of interest, serve as substrate for the nitrating agent (i.e., provide an alternative nitratable tyrosine residue), provide a nitrating agent neutralizing moiety such as antioxidant, or a combination thereof. The nitration shielding peptide can be a fusion protein that includes one or more additional domains such a protein transduction domain, a targeting signal, a purification tag, or any combination thereof. Exemplary nitration shielding peptides for reducing nitration of RhoA and PKG-1?, and methods of use thereof for treating pathologies, disease, and disorders associated with nitration of RhoA and PKG-1?, respectively are also provided.
Type:
Application
Filed:
September 15, 2014
Publication date:
March 19, 2015
Inventors:
Stephen M. Black, Ruslan Robertovich Rafitov
Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acid are disclosed that comprise the sequences that encodes consensus RSV F protein or immunogenic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Method of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.
Type:
Application
Filed:
April 10, 2013
Publication date:
March 19, 2015
Inventors:
David B. Weiner, Daniel Choo, Karuppiah Muthumani, Nyamekye Obeng-Adjei, Veronica Scott
Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
Type:
Grant
Filed:
February 2, 2012
Date of Patent:
March 17, 2015
Assignees:
Merial, Inc., Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
Type:
Grant
Filed:
June 28, 2012
Date of Patent:
March 17, 2015
Assignee:
InhibRx, LLC
Inventors:
Brendan Eckelman, John Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
Abstract: The present invention concerns a method for the production of 1,2-propanediol, comprising culturing a microorganism modified for an improved production of 1,2-propanediol in an appropriate culture medium and recovery of the 1,2-propanediol which may be further purified wherein the microorganism expresses a glycerol dehydrogenase (GlyDH) enzyme the inhibition of which activity by NAD+ and/or its substrate and/or its product is reduced. The present invention also relates to a mutant glycerol dehydrogenase (GlyDH) comprising at least one amino acid residue in the protein sequence of the parent enzyme replaced by a different amino acid residue at the same position wherein the mutant enzyme has retained more than 50% of the glycerol dehydrogenase activity of the parent enzyme and the glycerol dehydrogenase activity of the mutant GlyDH is less inhibited by NAD+ and/or by its substrate as compared to the parent enzyme and/or by its product as compared to the parent enzyme.
Type:
Grant
Filed:
July 30, 2010
Date of Patent:
March 17, 2015
Assignee:
Metabolic Explorer
Inventors:
Francois Voelker, Laurence Dumon-Seignovert, Isabelle Meynial-Salles, Philippe Soucaille
Abstract: The invention relates to the fields of molecular biology, medicine, virology and vaccine development. Because the different forms of the presently available vaccines all have their specific drawbacks, there is a need for alternative vaccine strategies. The current invention provides means and methods for such alternative vaccine strategies.
Type:
Grant
Filed:
March 7, 2011
Date of Patent:
March 17, 2015
Assignee:
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam
Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n -X- moieties shares sequence identity to each other -X- moiety, the protein is a ‘tandem protein’.
Abstract: A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.
Type:
Grant
Filed:
April 15, 2011
Date of Patent:
March 17, 2015
Assignee:
Herantis Pharma Oyj
Inventors:
Mart Saarma, Juha Lauren, Päivi Lindholm, Tonis Timmusk, Raimo Tuominen
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Abstract: A process for the production of glucose from a pretreated lignocellulosic feedstock is provided. The method comprises enzymatically hydrolyzing the pretreated lignocellulosic feedstock with cellulase enzymes to produce a hydrolyzate slurry comprising glucose and unhydrolyzed cellulose and fermenting the hydrolyzate slurry in a fermentation reaction to produce a fermentation broth comprising alcohol. A process stream is obtained comprising unhydrolyzed cellulose, which is then subjected to a denaturing step, preferably comprising exposing the unhydrolyzed cellulose to elevated temperatures, thereby producing a heat-treated stream comprising the unhydrolyzed cellulose. The heat-treated stream comprising unhydrolyzed cellulose is then further hydrolyzed with cellulase enzymes to hydrolyze the cellulose to glucose.
Type:
Grant
Filed:
July 29, 2008
Date of Patent:
March 17, 2015
Assignee:
Iogen Energy Corporation
Inventors:
Jeffrey S. Tolan, Brian Foody, Stephen Rowland
Abstract: The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.
Type:
Grant
Filed:
June 2, 2011
Date of Patent:
March 17, 2015
Assignee:
Pfizer Inc
Inventors:
Alan Daniel Brown, Heather Lynn Davis, David P. Gervais, Lyn Howard Jones, James R. Merson, David Cameron Pryde, David R. Stead, Michael J. McCluskie, Jennifer Marie Thorn, Paul Robert Mehelic, Parag Ashok Kolhe, Keshab Bhattacharya, Jari Ilmari Finneman, Erin Kristen Parsons, Nickolas Anastasiou
Abstract: The invention disclosed herein relates to methods and materials for producing simvastatin and related compounds such as huvastatin. In particular, the disclosure teaches that variants of the LovD acyltransferase polypeptide can be engineered to exhibit properties that facilitate their use in the production of simvastatin and/or huvastatin. The materials and processes disclosed herein are designed so that fermentation facilities currently producing lovastatin can be converted to producing simvastatin and related compounds with minimal modifications.
Type:
Grant
Filed:
October 8, 2010
Date of Patent:
March 17, 2015
Assignee:
The Regents of the University of California
Abstract: The invention provides certain embodiments relating to methods and compositions for incorporating non-natural amino acids into a polypeptide or protein by utilizing a mutant or modified aminoacyl-tRNA synthetase to charge the non-natural amino acid to a the corresponding tRNA. In certain embodiments, the tRNA is also modified such that the complex forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with unmodified tRNA/aminoacyl-tRNA synthetase pairs.
Type:
Grant
Filed:
August 16, 2013
Date of Patent:
March 17, 2015
Assignee:
California Institute of Technology
Inventors:
Pin Wang, Inchan Kwon, Soojin Son, Yi Tang, David Tirrell
Abstract: This invention relates to isolated Clostridium botulinum propeptides and neurotoxins, isolated nucleic acid molecules encoding Clostridium botulinum propeptides and neurotoxins, methods of expression, treatment methods, and methods of detecting neurotoxin trafficking. The isolated Clostridium botulinum propeptides have a light chain region; a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond; an intermediate region connecting the light and heavy chain regions and comprising a highly specific protease cleavage site; and an S6 peptide sequence according to SEQ ID NO:2 positioned upstream from, but not attached directly to, the N-terminus of the neurotoxin propeptide at the light chain region to enable site specific attachment of cargo.
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Type:
Application
Filed:
September 9, 2014
Publication date:
March 12, 2015
Inventors:
Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Hui WEI, Aaron P. YAMNIUK, Vidhyashankar RAMAMURTHY, Alexander T. KOZHICH, Martin J. CORBETT, Stanley Richard KRYSTEK, JR.
Abstract: The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.
Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of funcational effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.
Type:
Application
Filed:
August 18, 2014
Publication date:
March 12, 2015
Applicant:
President and Fellows of Harvard College
Inventors:
David R. Liu, John Anthony Zuris, David B. Thompson
Abstract: The invention relates to methods and compositions for treating or inhibiting infection of Clostridium difficile. The methods and compositions generate rapid immune responses that inhibit future infection, and/or neutralize the toxicity caused by C. difficile infection.
Type:
Application
Filed:
November 29, 2012
Publication date:
March 12, 2015
Applicant:
Board of Trustees of Michigan State University
Abstract: Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene.
Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
Type:
Application
Filed:
September 18, 2014
Publication date:
March 12, 2015
Inventors:
Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
Abstract: The present disclosure provides opsins, including variant opsins with increased activity and/or increased trafficking to the plasma membrane. The opsins are useful in therapeutic and screening applications, which are also provided.
Abstract: Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging.
Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
Type:
Grant
Filed:
June 16, 2011
Date of Patent:
March 10, 2015
Assignee:
Zoetis P&U LLC
Inventors:
David E. Lowery, Troy E. Fuller, Michael J. Kennedy
Abstract: Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mold Dictyostelium discoideum and used to specifically degrade lipopolysaccharide (LPS). Enzymatic degradation permits residues of the LPS molecule, including immunogenic epitopes of the core oligosaccharide portion of the LPS, to remain unmodified during this enzymatic removal of fatty acids from the lipid A region of the LPS molecule.
Type:
Grant
Filed:
November 23, 2006
Date of Patent:
March 10, 2015
Assignee:
National Research Council of Canada
Inventors:
Andrew Cox, Dhamodharan Neelamegan, Ian Schoenhofen, Frank St. Michael, James Richards
Abstract: The invention provides seed and plants of tomato hybrid PS02420487 and the parent lines thereof. The invention thus relates to the plants, seeds and tissue cultures of tomato hybrid PS02420487 and the parent lines thereof, and to methods for producing a tomato plant produced by crossing such plants with themselves or with another tomato plant, such as a plant of another genotype. The invention further relates to seeds and plants produced by such crossing. The invention further relates to parts of such plants, including the fruit and gametes of such plants.
Abstract: Provided is a protein quantitation standard having polypeptides of different molecular weights that functions as a mass quantitation standard in one lane of an electrophoretic gel. The protein quantitation standard includes unstained polypeptides having different electrophoretic mobilities that are present in different quantities, such that the bands in the gel have different intensities when visualized. The protein quantitation standard can also contain prestained polypeptides that function as visual molecular weight markers. Also provided are methods of determining the mass of a target polypeptide or protein using the protein quantitation standard.
Type:
Grant
Filed:
June 28, 2013
Date of Patent:
March 10, 2015
Assignee:
Bio-Rad Laboratories, Inc.
Inventors:
Joseph S. Siino, Jr., Dennis C. Yee, Lee O. Lomas
Abstract: The object of the present invention is to provide: a test kit for an antibody titer or an antibody against a periodontal disease-causing bacterium in a blood sample, which enables the testing on a periodontal disease in patients having a wide scope of immunotypes with high accuracy and can be treated by an automated device at a high speed; a periodontal disease-causing bacterium antigen protein which can be suitably used in the kit; a method for testing an antibody titer or the presence of an antibody in a blood sample using the kit; and a kit for typing strains of Porphyromonas gingivalis.
Abstract: Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.
Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.
Type:
Grant
Filed:
October 29, 2008
Date of Patent:
March 10, 2015
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
Abstract: The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity.
Type:
Grant
Filed:
January 6, 2010
Date of Patent:
March 10, 2015
Assignee:
Ann & Robert H. Lurie Children's Hospital of Chicago
Inventors:
Mary Jessica Hendrix, Lynne-Maire Postovit, Richard Edward Barnet Seftor, Elisabeth Ann Seftor
Abstract: The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor.
Type:
Grant
Filed:
April 24, 2013
Date of Patent:
March 10, 2015
Assignee:
University of South Florida
Inventors:
Young Min Ju, Francis Moussy, Thomas J. Koob
Abstract: Alpha-amylases from Bacillus subtilis (AmyE), variants thereof, nucleic acids encoding the same, and host cells comprising the nucleic acids are provided. Methods of using AmyE or variants thereof are disclosed, including liquefaction and/or saccharification of starch. Such methods may yield sugars useful for ethanol production or high fructose corn syrup production. In some cases, the amylases can be used at low pH, in the absence of calcium, and/or in the absence of a glucoamylase.
Type:
Grant
Filed:
October 25, 2012
Date of Patent:
March 10, 2015
Assignee:
Danisco US Inc.
Inventors:
Luis G. Cascao-Pereira, William A. Cuevas, David A. Estell, Sang-Kyu Lee, Scott D. Power, Sandra W. Ramer, Amr Toppozada, Louise Wallace
Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternately, the compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.